List of Excipients in Branded Drug THIAMINE HYDROCHLORIDE

« Back to Dashboard

Generic Drugs Containing THIAMINE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Henry Schein Inc	thiamine hydrochloride	0404-9799	SODIUM HYDROXIDE
Henry Schein Inc	thiamine hydrochloride	0404-9799	WATER
Henry Schein Inc	thiamine hydrochloride	0404-9963	MONOTHIOGLYCEROL
Henry Schein Inc	thiamine hydrochloride	0404-9963	SODIUM HYDROXIDE
Henry Schein Inc	thiamine hydrochloride	0404-9963	WATER
Heritage Pharmaceuticals Inc d/b/a Avet Pharmaceuticals Inc	thiamine hydrochloride	23155-933	CHLOROBUTANOL HEMIHYDRATE

What are the Most Frequently-Used Excipients in THIAMINE HYDROCHLORIDE?

# Of NDCs	Excipient
3	CHLOROBUTANOL
6	CHLOROBUTANOL HEMIHYDRATE
14	MONOTHIOGLYCEROL
14	SODIUM HYDROXIDE
14	WATER

Thiamine Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: October 12, 2026

Thiamine hydrochloride is a low-cost, highly established vitamin B1 active with limited active-ingredient patent protection and broad formulation flexibility. Commercial opportunity is concentrated in differentiated delivery systems, hospital-ready injectables, oral liquid stability, pediatric products, premixes, and regulated nutrition products rather than in new-molecule exclusivity.

The most important formulation constraint is chemical stability. Thiamine hydrochloride is water soluble but sensitive to alkaline conditions, heat, light, oxidation-reduction reactions, and certain preservative systems. Excipient selection should maintain an acidic microenvironment, minimize reactive impurities, control moisture, and support the intended route of administration. [1-4]

What is thiamine hydrochloride and where is it used?

Thiamine hydrochloride is the hydrochloride salt of thiamine, or vitamin B1. It is used to prevent or treat thiamine deficiency, including deficiency associated with alcoholism, malnutrition, malabsorption, prolonged parenteral nutrition, bariatric surgery, and selected metabolic disorders.

Attribute	Thiamine hydrochloride
Active ingredient	Thiamine hydrochloride
Vitamin	B1
Molecular formula	C12H17ClN4OS
Primary routes	Oral, intramuscular, intravenous
Solubility profile	Water soluble
Main clinical uses	Thiamine deficiency, beriberi, Wernicke-related deficiency management
Commercial categories	Prescription medicines, OTC supplements, medical nutrition, food fortification, veterinary products
Patent position	Mature active ingredient with limited practical compound-patent protection
Main formulation risk	Chemical degradation in unfavorable pH, heat, light, or reactive excipient environments

The active is commonly supplied as a crystalline powder for tablets, capsules, oral solutions, injectable products, premixes, and combination vitamin formulations. FDA labeling identifies thiamine hydrochloride injection for treatment of thiamine deficiency and specifies parenteral administration when oral administration is not feasible or absorption is impaired. [1]

What excipients are suitable for thiamine hydrochloride formulations?

Suitable excipients depend on route, dose, target patient, and regulatory category. The central strategy is to use low-reactivity excipients and preserve an acidic formulation environment.

Formulation type	Core excipient strategy	Principal risks
Immediate-release tablet	Microcrystalline cellulose, lactose or mannitol, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate	Moisture uptake, blend segregation, compression variability
Hard capsule	Lactose, microcrystalline cellulose, starch, magnesium stearate, silicon dioxide	Powder flow, shell moisture, content uniformity
Oral solution	Purified water, acidic buffer, suitable sweetener, flavor, chelator where justified	pH drift, light exposure, microbial growth, preservative compatibility
Oral drops	Water, acidifying agent, sweetener, viscosity modifier, preservative where permitted	Dose uniformity, microbial control, packaging adsorption
Injectable solution	Water for Injection, sodium chloride where required, pH adjusters, nitrogen headspace or oxygen-control measures	Oxidation, light, particulate formation, terminal sterilization stress
Orally disintegrating tablet	Mannitol, crospovidone, crospovidone or croscarmellose, low-level lubricant	Moisture sensitivity, taste, friability
Powder or sachet	Mannitol, maltodextrin, microcrystalline cellulose, flavor system, flow aid	Hygroscopicity, segregation, reconstitution performance
Premix or nutrition product	Compatible carbohydrate, amino-acid, mineral, and vitamin matrix	Chemical interaction with sulfites, copper, iron, alkaline salts, and heat

Which tablet excipients provide the best commercial balance?

Immediate-release tablets offer the lowest development risk. Microcrystalline cellulose and mannitol provide robust compaction and acceptable mouthfeel. Lactose can reduce cost but requires compatibility and moisture assessment. Croscarmellose sodium or crospovidone can support rapid disintegration at low concentrations.

Magnesium stearate is widely used, but excessive levels or prolonged lubrication can slow dissolution. Colloidal silicon dioxide can improve flow, particularly where the formulation uses low-dose thiamine hydrochloride and requires tight content uniformity.

For high-volume generic products, the preferred design is usually a simple, low-moisture formulation with direct compression or dry granulation. Wet granulation should be justified by manufacturability because water exposure adds processing complexity and may increase degradation risk.

Which excipients are suitable for oral liquids?

Oral liquids require tighter control of pH, light, oxygen, and microbial contamination than conventional tablets. An acidic formulation is generally preferred because thiamine is less stable under alkaline conditions. Citric acid, hydrochloric acid, citrate buffers, or other pharmaceutically acceptable acidifying systems may be evaluated during development. The final buffer system must avoid excessive ionic strength and must remain compatible with taste, preservative performance, and container closure materials.

Sucrose, sorbitol, glycerol, and maltitol can provide sweetness and body. Pediatric products may use sugar-free systems based on sorbitol, glycerol, sucralose, or other permitted sweeteners. Flavor systems should be screened for peroxide impurities and pH effects.

Preservatives require particular attention. Benzoate or sorbate systems may be appropriate in acidic products, but the concentration, pH, and local regulatory requirements must support antimicrobial effectiveness. Thiamine-containing products should be screened against sulfites and other reactive preservative systems because sulfites can degrade thiamine. [2, 3]

What excipients should be avoided or tightly controlled?

Thiamine hydrochloride is vulnerable to excipient-driven instability. The highest-risk materials include alkaline buffers, sulfite-containing ingredients, oxidizing contaminants, and excipients with high moisture or peroxide levels.

Alkaline materials

Alkaline pH accelerates thiamine degradation. Sodium bicarbonate, carbonate systems, strongly basic buffers, and alkaline mineral components should be avoided unless compatibility data support their use. The risk is especially relevant in effervescent products, electrolyte products, and mineral-vitamin combinations.

Sulfites and bisulfites

Sodium metabisulfite and related sulfiting agents can react with thiamine. Sulfite-containing excipients, process aids, raw materials, and compounded nutrition components require specific compatibility review. The issue is commercially important for parenteral products and compounded formulations, where sodium metabisulfite may be used as an antioxidant or preservative in other drug products.

Peroxide-forming excipients

Polyethylene glycol, povidone, crospovidone, and some polymeric excipients can contain or develop peroxide impurities. These materials are not automatically unsuitable, but supplier specifications and incoming-lot controls should include peroxide risk where the formulation is sensitive to oxidation.

Reactive minerals and trace metals

Copper, iron, and other trace metals can catalyze degradation pathways in vitamin mixtures. Chelators such as disodium edetate may be evaluated in liquid products, although their use must be justified by stability and safety data. Metal control is often more effective when applied through raw-material specifications, purified water controls, and equipment qualification rather than by adding a chelator alone.

How should thiamine hydrochloride formulations be designed for stability?

A commercial stability program should evaluate pH, light, oxygen, temperature, moisture, and container closure interaction.

Stability variable	Recommended development approach
pH	Screen an acidic range and identify the minimum practical buffer capacity
Light	Use amber glass, opaque plastic, light-protective overwrap, or controlled storage labeling
Oxygen	Evaluate nitrogen sparging, low-oxygen headspace, antioxidant compatibility, and container permeability
Temperature	Conduct accelerated and long-term studies with particular attention to heat exposure during processing
Moisture	Use low-moisture excipients, controlled humidity, desiccants where justified, and high-barrier packaging
Metals	Control trace metals in water, excipients, equipment, and packaging components
Microbiology	Validate preservative effectiveness for multidose liquids and comply with sterile-product controls for injections
Assay method	Use a stability-indicating chromatographic method capable of separating degradation products

The packaging system can create more commercial value than a minor excipient substitution. Blister packaging, high-barrier bottles, amber glass, unit-dose ampoules, and oxygen-controlled closures can extend shelf life and support premium positioning. A stability package that permits room-temperature distribution can reduce logistics costs for hospital and international markets.

What formulations are protected by thiamine hydrochloride patents?

Thiamine hydrochloride has a mature active-ingredient history, so commercial exclusivity is unlikely to come from a new chemical entity patent. Potentially protectable subject matter includes:

• A specific stabilized oral liquid with defined pH and preservative concentrations.
• A low-degradation injectable composition with a particular buffer and oxygen-control system.
• A sustained-release or targeted-delivery formulation.
• A taste-masked pediatric dosage form.
• A combination product with defined ratios of thiamine and other nutrients.
• A manufacturing process that reduces degradation or improves impurity control.
• A premix or parenteral nutrition composition with defined compatibility limits.
• A device-linked delivery system or unit-dose presentation.

A formulation patent must provide more than the routine use of common excipients. The strongest claims generally require a narrow combination of composition, pH, concentration, packaging, process conditions, and demonstrated stability improvement. Broad claims covering thiamine hydrochloride with conventional fillers, binders, lubricants, or sweeteners are vulnerable to obviousness and lack-of-technical-effect arguments.

What is the Orange Book status of thiamine hydrochloride?

The FDA Orange Book is relevant only to approved prescription drug products that are listed by the agency. OTC supplements and food products are outside the Orange Book system. [5]

Thiamine hydrochloride products may appear in FDA prescription-drug databases depending on sponsor, dosage form, strength, and marketing status. An Orange Book listing does not create a new patent right. It identifies approved products and, where applicable, patents and regulatory exclusivities submitted by the sponsor.

For a proposed generic product, the relevant diligence questions are:

1. Whether a listed reference product exists for the target dosage form and strength.
2. Whether the reference product has listed patents.
3. Whether any listed patent claims the active ingredient, formulation, method of use, or device.
4. Whether the proposed product requires a Paragraph IV certification.
5. Whether the product can proceed through an abbreviated new drug application, a suitability petition, or a full 505(b)(2) pathway.

Because thiamine hydrochloride is an old active, regulatory complexity often lies in reference-product selection, dosage-form equivalence, sterile manufacturing, and labeling rather than active-ingredient patent barriers.

When does thiamine hydrochloride lose exclusivity?

Thiamine hydrochloride does not have a meaningful modern new-molecule exclusivity timeline. The active ingredient has been used for decades, and the core commercial market is generally open to multiple manufacturers.

Exclusivity can still arise from a specific product:

Exclusivity type	Relevance to thiamine hydrochloride
New chemical entity exclusivity	Not commercially relevant to this established vitamin
New formulation exclusivity	Possible for an approved innovative dosage form, subject to FDA qualification
Orphan-drug exclusivity	Possible only for a qualifying rare-disease indication
Pediatric exclusivity	Possible if FDA requirements are met, but not inherent to the ingredient
Patent exclusivity	Possible for formulation, method, process, packaging, or device claims
Trade-secret protection	Relevant to process controls, impurity reduction, and premix manufacturing
Regulatory exclusivity for supplements	Generally not available under the drug framework

Generic or competing entry may therefore occur immediately for unpatented, established dosage forms, subject to approval, manufacturing capability, and applicable national rules.

What Paragraph IV challenges and litigation risks exist?

A Paragraph IV challenge is relevant only when a generic applicant references an FDA-listed drug product with an unexpired patent. For a mature thiamine hydrochloride product, the most probable targets would be formulation, method-of-use, or device patents rather than the basic active ingredient.

Potential litigation issues include:

• Whether a generic oral liquid infringes a pH or preservative claim.
• Whether an injectable product falls within a stabilized composition claim.
• Whether a method-of-use patent covers treatment of a specific deficiency population.
• Whether a manufacturing process claim can be infringed without access to the generic's process.
• Whether a patent listed in the Orange Book properly claims the approved product.
• Whether a settlement restricts launch timing or permits an authorized generic.

The economic value of litigation is likely to be limited for basic vitamin tablets and larger for differentiated injectable, pediatric, or combination products. No broadly recognized, market-defining Paragraph IV dispute is inherent in thiamine hydrochloride itself. Product-specific diligence must rely on current FDA and court records. [5, 6]

Which companies are competing in thiamine hydrochloride?

Competition is fragmented across pharmaceutical, nutrition, contract manufacturing, and ingredient-supply markets. Relevant competitor groups include:

• Generic injectable manufacturers.
• OTC vitamin brands.
• Hospital and clinical-nutrition suppliers.
• Global API manufacturers.
• Premix and food-fortification companies.
• Veterinary pharmaceutical manufacturers.
• Contract development and manufacturing organizations.

The market is generally price sensitive for standard tablets and capsules. Differentiation is stronger in sterile injections, pediatric liquids, ready-to-administer presentations, high-concentration products, and products designed for malabsorption or acute-care use.

Supplier qualification can create a practical barrier. Buyers may require validated impurity profiles, low bioburden or endotoxin levels, reliable particle-size distribution, audit history, pharmacopeial compliance, and continuity of supply. These factors can support premium pricing even when patents are absent.

What are the strongest commercial opportunities?

Hospital-ready injectable products

Parenteral thiamine is used where rapid treatment or unreliable gastrointestinal absorption is a concern. Commercial advantages include ready-to-use syringes, low-volume presentations, clear labeling, barcode compatibility, tamper evidence, and reduced preparation steps.

The principal barriers are sterile manufacturing, particulate control, container closure integrity, extractables and leachables, and stability under shipping conditions.

Pediatric oral liquids

Pediatric products can differentiate through accurate dosing, sugar-free formulations, palatable flavors, preservative systems suitable for children, and oral syringes with dose markings. A stable product that does not require refrigeration has a strong distribution advantage.

Orally disintegrating and chewable products

These products address swallowing difficulty and adherence. Mannitol-based systems, taste masking, rapid disintegration, and low moisture exposure are central development issues. Commercial value depends on proving a meaningful use advantage over inexpensive tablets.

Medical nutrition and premixes

Thiamine is used in multivitamin injections, parenteral nutrition, enteral nutrition, and fortified products. The opportunity is less likely to depend on a standalone thiamine product and more likely to involve compatible premixes, stable multivitamin systems, and improved manufacturing controls.

Veterinary products

Veterinary applications offer a separate channel with liquid, injectable, and feed-additive opportunities. Species-specific dosing, packaging, and distribution can reduce direct competition with human pharmaceutical products.

How does thiamine hydrochloride compare with thiamine mononitrate?

Factor	Thiamine hydrochloride	Thiamine mononitrate
Water solubility	Higher	Lower
Common use	Pharmaceuticals, injections, oral products	Food fortification, supplements, dry blends
Formulation advantage	Suitable for aqueous solutions and parenteral products	Better suited to dry, low-moisture systems
Moisture considerations	Requires liquid and solid stability controls	Often preferred where low hygroscopicity is important
Commercial positioning	Clinical and pharmaceutical delivery	Fortification and dry nutritional products

The salt choice should follow the product format. Thiamine hydrochloride is generally favored where aqueous solubility and injectable use matter. Thiamine mononitrate may be more efficient for dry premixes, fortified foods, and formulations where moisture management is a priority. [2, 4]

What manufacturing and IP barriers affect market entry?

The main barriers are technical and operational rather than compound-patent based.

For tablets, the barriers are low. A manufacturer needs qualified API supply, validated blending and compression, dissolution performance, stability data, and compliant packaging.

For oral liquids, the barriers rise because the sponsor must control pH, microbial quality, preservative effectiveness, light, oxygen, taste, and dose uniformity.

For injections, the barriers are materially higher. The manufacturer must demonstrate aseptic or terminal-sterilization control, endotoxin compliance, particulate limits, container closure integrity, sterility, stability, and reliable commercial-scale filling.

Trade secrets can be important in impurity control, low-oxygen processing, premix order of addition, and packaging selection. These protections may support customer retention but do not prevent a technically competent competitor from developing an independent product.

Key Takeaways

• Thiamine hydrochloride is a mature, low-cost vitamin B1 active with limited practical active-ingredient patent protection.
• The main formulation issue is stability under alkaline, thermal, light, oxidative, sulfite-containing, and high-moisture conditions.
• Acidic pH control, low-reactivity excipients, metal control, protective packaging, and oxygen management are the core formulation tools.
• Standard tablets and capsules are highly competitive and have low entry barriers.
• Injectable, pediatric liquid, orally disintegrating, ready-to-administer, and premix products offer stronger commercial differentiation.
• Orange Book and Paragraph IV risks are product specific. They are more likely to involve formulation, method-of-use, process, or device claims than the thiamine molecule.
• The strongest defensible positions combine formulation claims with demonstrated stability, manufacturing controls, packaging, and clinical-use advantages.
• Thiamine hydrochloride is generally preferable to thiamine mononitrate for aqueous and parenteral products, while mononitrate may be preferable for dry fortification systems.

FAQs

Is thiamine hydrochloride suitable for pediatric formulations?

Yes. Oral solutions, drops, syrups, chewables, and orally disintegrating tablets are viable formats. The formulation must address palatability, dosing accuracy, preservative exposure, sugar content, pH, and microbial stability.

Can thiamine hydrochloride be used in parenteral nutrition?

Yes. It is used in injectable vitamin and nutrition products. Compatibility with sulfites, trace metals, amino acids, electrolytes, light, and heat must be evaluated before commercial use.

Does thiamine hydrochloride require a preservative?

Not necessarily. Single-dose sterile injections generally avoid preservatives where feasible. Multidose liquids may require a validated preservative system, but the selected preservative must be compatible with thiamine and the final pH.

Is a thiamine hydrochloride formulation patentable?

A formulation may be patentable if it includes a novel and non-obvious composition, process, packaging configuration, or delivery system supported by technical results. Conventional use of common tablet excipients is generally a weak basis for broad patent claims.

Which packaging is best for thiamine hydrochloride products?

The choice depends on dosage form. Amber glass or opaque high-barrier plastic is suitable for light-sensitive liquids, while alu-alu blisters, high-barrier bottles, desiccants, and oxygen-controlled closures can support solid-dose stability.

References

1. U.S. Food and Drug Administration. (n.d.). Thiamine hydrochloride injection prescribing information. DailyMed. https://dailymed.nlm.nih.gov/

2. National Center for Biotechnology Information. (n.d.). Thiamine. In PubChem compound summary. https://pubchem.ncbi.nlm.nih.gov/

3. World Health Organization. (2009). WHO technical report series 957: WHO guidelines for the production and quality control of pharmaceutical products containing vitamins and minerals. World Health Organization.

4. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

6. U.S. Food and Drug Administration. (2024). Electronic Orange Book patent and exclusivity information. https://www.accessdata.fda.gov/scripts/cder/ob/agen/index.cfm